Description: Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Home Page: www.glpg.com
Generaal De Wittelaan L11 A3
Mechelen,
2800
Belgium
Phone:
32 1 534 29 00
Officers
| Name | Title |
|---|---|
| Dr. Paulus A. Stoffels M.D., Ph.D. | CEO, Chairman, Interim Head of R&D |
| Mr. Thad Huston C.M.A. | Executive VP, CFO & COO |
| Ms. Sofie Van Gijsel | Head of Investor Relations |
| Ms. Valeria Cnossen | Executive VP & General Counsel |
| Marieke Vermeersch | Head of Corporate Communication |
| Ms. Annelies Missotten | Executive VP & Chief Human Resources Officer |
| Ms. Ellen Van Der Aar | Head of Development |
| Mr. Philippe Alen M.B.A., Ph.D., Pharm.D. | Senior VP & Head of Business Development |
| Ms. Alice Dietrich | Head of Medical Affairs |
| Dr. Pierre J.M.B. Raboisson Ph.D., Pharm.D. | Head of Small Molecules Discovery & Senior VP |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 163.9344 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5861 |
| Price-to-Sales TTM: | 6.5063 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1123 |